Difference between revisions of "Template:Major side effects of bicalutamide alone"

From blackwiki
Jump to navigation Jump to search
imported>Medgirl131
imported>Medgirl131
Line 1: Line 1:
{| class="wikitable {{{state<includeonly>|floatright</includeonly>}}} sortable" style="font-size:small; text-align:left; margin-left:auto; margin-right:auto; border:none;"
+
{| class="wikitable {{{state<includeonly>|floatright</includeonly>}}}" style="font-size:small; text-align:left; margin-left:auto; margin-right:auto; border:none;"
 
|+ {{Navbar|Major side effects of bicalutamide alone|mini=y}} {{Resize|105%|Major side effects of {{No selflink|bicalutamide}} alone}}
 
|+ {{Navbar|Major side effects of bicalutamide alone|mini=y}} {{Resize|105%|Major side effects of {{No selflink|bicalutamide}} alone}}
 
|-
 
|-

Revision as of 13:07, 13 November 2018

Major side effects of Template:No selflink alone

Frequency Class Side effect
Very common
(≥10%)
Reproductive system
and breast disorders
Breast tendernessa
Gynecomastiaa
Common
(≥1% and <10%)
General and psychiatric
disorders
Asthenia
Decreased libido
Erectile dysfunction
Hot flashes
Skin and subcutaneous
tissue disorders
Decreased body hair
Hepato-biliary disorders Elevated liver enzymesb
Uncommon
(≥0.1% and <1%)
Immune system disorders Hypersensitivity reactions,
including angioedema and hives
Rare (<0.1%)
and unknown
Respiratory, thoracic, and
mediastinal disorders
Interstitial lung diseasec
Skin and subcutaneous
tissue disorders
Sensitivity to light
Hepato-biliary disorders Liver toxicityd
Footnotes and sources
a = Incidence of breast changes of up to 80 to 90%. Mild-to-moderate in 90% of cases. Incidence greatly decreased in combination with castration.
b = Elevated liver enzymes rarely severe and usually transient, resolving or improving with continued therapy or with discontinuation. Incidence of 3.4% relative to 1.9% for placebo in a high-dose (150 mg/day) 4,000-patient trial.
c = Six case reports of interstitial lung disease published (as of 2016). Incidence of 0.01% (12 patients) in an 87,000-patient cohort.
d = Six case reports of hepatotoxicity published (as of 2018). No cases in a high-dose (150 mg/day) 4,000-patient trial (suggesting incidence of <0.03%).
Sources: [1][2][3][4][5][6][7]

References

  1. Mcleod DG (September 2002). "Emerging role of adjuvant hormonal therapy". Urology. 60 (3 Suppl 1): 13–20, discussion 21. doi:10.1016/S0090-4295(02)01562-5. PMID 12231039.
  2. https://pdf.hres.ca/dpd_pm/00009096.PDF
  3. Bennett CL, Raisch DW, Sartor O (October 2002). "Pneumonitis associated with nonsteroidal antiandrogens: presumptive evidence of a class effect". Annals of Internal Medicine. 137 (7): 625. doi:10.7326/0003-4819-137-7-200210010-00029. PMID 12353966. An estimated 0.77% of the 6,480 nilutamide-treated patients, 0.04% of the 41,700 flutamide-treated patients, and 0.01% of the 86,800 bicalutamide-treated patients developed pneumonitis during the study period.
  4. Molina Mancero, Guillermo; Picón, Xavier; Di Tullio, Fernando; Ernst, Glenda; Dezanzo, Pablo; Salvado, Alejandro; Chertcoff, Julio F (2016). "Neumonía intersticial inducida por bloqueo androgénico máximo como tratamiento de cáncer de próstata avanzado" [Fatal interstitial lung disease associated with maximum androgen blockade. Report of one case]. Revista médica de Chile. 144 (10): 1356–1359. doi:10.4067/S0034-98872016001000017. ISSN 0034-9887.
  5. Lee K, Oda Y, Sakaguchi M, Yamamoto A, Nishigori C (May 2016). "Drug-induced photosensitivity to bicalutamide - case report and review of the literature". Photodermatol Photoimmunol Photomed. 32 (3): 161–4. doi:10.1111/phpp.12230. PMID 26663090.
  6. Gretarsdottir, Helga M.; Bjornsdottir, Elin; Bjornsson, Einar S. (2018). "Bicalutamide-Associated Acute Liver Injury and Migratory Arthralgia: A Rare but Clinically Important Adverse Effect". Case Reports in Gastroenterology. 12 (2): 266–270. doi:10.1159/000485175. ISSN 1662-0631. no-break space character in |first1= at position 6 (help); no-break space character in |first3= at position 6 (help)
  7. Anderson J (March 2003). "The role of antiandrogen monotherapy in the treatment of prostate cancer". BJU Int. 91 (5): 455–61. doi:10.1046/j.1464-410X.2003.04026.x. PMID 12603397.